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Abstract
Purpose The aim of this study was to evaluate the safety
and efficacy of topical besifloxacin ophthalmic suspension
0.6% compared with gatifloxacin ophthalmic solution 0.3%
in the treatment of bacterial conjunctivitis in neonates.
Methods This was a multicenter, randomized, double-
masked, parallel group study. Subjects B31 days of age
with severity grade C1 (scale 0–3) for both conjunctival
discharge and conjunctival hyperemia were randomized to
besifloxacin or gatifloxacin instilled three times daily for 7
days, and completed five study visits (three clinic visits and
two phone calls). Primary endpoints included clinical
resolution (absence of both conjunctival discharge and
conjunctival hyperemia) at visit 5 (day 8 or 9) and ocular
and non-ocular treatment-emergent adverse events (AEs).
Bacterial eradication was a secondary endpoint.
Results Thirty-three subjects were included in the intent-
to-treat (ITT) population. All were aged\28 days, with a
mean (standard deviation) age of 15.5 days (6.0), and
57.6% were female. Twenty-two subjects had culture-
confirmed conjunctivitis in at least one eye (modified ITT
[mITT] population), most often with Gram-positive bac-
teria. Visit 5 clinical resolution and bacterial eradication
rates were comparable among besifloxacin- and gati-
floxacin-treated study eyes (clinical resolution: 12/16
[75.0%] vs. 12/17 [70.6%] for the ITT population, and
11/13 [84.6%] vs. 7/9 [77.8%] for the mITT population;
bacterial eradication: 12/13 [92.3%] vs. 8/9 [88.9%] for the
mITT population, respectively). No AEs were reported in
the besifloxacin treatment group, and AEs reported in the
gatifloxacin group were considered not treatment-related.
Conclusions In this small study in neonates, both besifloxacin
and gatifloxacin appeared effective and safe in the treatment of
bacterial conjunctivitis. Larger studies are warranted.
Key Points
This study compared the use of two different topical
antibiotics (besifloxacin and gatifloxacin, each
administered three times daily for 7 days) in 33
neonatal subjects with bacterial conjunctivitis, a
condition for which there are little published data in
this age group.
High rates of clinical resolution were observed with
both antibiotics; however, bacterial eradication
occurred earlier with besifloxacin.
Both antibiotics were well tolerated in this small
group of neonates and there were no adverse events
with besifloxacin treatment.
1 Background
Neonatal conjunctivitis is an acute condition characterized
by conjunctival erythema, swelling, and mucopurulent
discharge occurring within the first 30 days of life [1–3].
The data in this article were presented at the Annual Meeting of the
Association for Research in Vision and Ophthalmology, Orlando, FL,
USA, 4–8 May 2014 (poster #5790-B0215).
& Christine M. Sanfilippo
Christine.sanfilippo@bausch.com
1 Bausch & Lomb, 1400 North Goodman Street, Rochester,
NY 14609, USA
2 38, rue de Villiers, 92300 Levallois Perret, France
Drugs R D (2017) 17:167–175
DOI 10.1007/s40268-016-0164-6
While viruses are a common cause of pediatric conjunc-
tivitis, studies conducted in North America that included
children\5 years of age with purulent conjunctival dis-
charge identified a bacterial pathogen in 65–80% of cul-
tures [4–6]. The American Academy of Ophthalmology
recommends conjunctival cultures be taken from all cases
of suspected neonatal bacterial conjunctivitis [7]. Con-
junctivitis in a newborn can pose a risk for the development
of secondary ocular infections, including endophthalmitis
and keratitis (in cases of gonococcal etiology) [1, 8], per-
manent eye damage, and even blindness, although the latter
is rare in industrialized countries [8]. Systemic complica-
tions such as pneumonitis, meningitis, and septicemia are
also possible [1, 2, 8].
The recommended management of suspected bacterial
neonatal conjunctivitis includes the use of systemic and/or
topical antibiotics [1, 4]. Topical fluoroquinolones are often
preferred for the treatment of bacterial conjunctivitis in the
general population due to their rapid bactericidal activity,
broad spectrum of activity, and low toxicity [9, 10].
Although some studies have included neonates within a
broader population [11–14], to our knowledge there are no
published reports of topical fluoroquinolones used specifi-
cally in neonatal conjunctivitis, with the exception of a
single study published in abstract form only [15].
Besifloxacin is a topical fluoroquinolone and represents the
first chloro-fluoroquinolone developed specifically for oph-
thalmic use. The broad spectrum activity of besifloxacin
includes potent in vitro activity against drug-resistant strains
such as ciprofloxacin-resistant, methicillin-resistant S. aureus
(MRSA) and methicillin-resistant coagulase-negative Sta-
phylococcus species [16–19]. Besifloxacin ophthalmic sus-
pension 0.6% (Besivance; Bausch & Lomb, Tampa, FL,
USA) is approved by the US FDA for the treatment of bac-
terial conjunctivitis, with a recommended dosing regimen of
three times daily for 7 days; this indication is based on clinical
studies conducted in patients C1 year of age [20]. A prior
analysis of pediatric (ages 1–17; n = 815) subgroup data
from three bacterial conjunctivitis studies in patients of all
ages demonstrated significant and high rates of clinical res-
olution (88.1%) and bacterial eradication (82.8%) with besi-
floxacin treatment at day 8 or 9 (visit 3) compared with
vehicle (p B 0.009). Rates of clinical resolution and bacterial
eradication were similar between besifloxacin and moxi-
floxacin treatment groups for patients aged 1–17 at all visits
(P=NS). Among subjects aged 1 year, there was statistically
significant bacterial eradication at day 5 ± 1 (visit 2) com-
pared with vehicle (p = 0.04) [21].
The current study was designed to evaluate the safety and
efficacy of besifloxacin ophthalmic suspension 0.6% com-
pared with gatifloxacin ophthalmic solution 0.3% (Zymar;
Allergan, Irvine, CA, USA) when administered three times
daily for 7 days in neonates with bacterial conjunctivitis.
Gatifloxacin was selected as an active comparator because it
has an antibacterial action similar to besifloxacin, they both
inhibit bacterial DNA gyrase and topoisomerase IV [22], and
because it was previously reported to be safe when admin-
istered three times daily in neonates [23].
2 Materials and Methods
2.1 Study Design and Procedures
This multicenter, randomized, double-masked, active-con-
trolled, parallel group study (NCT01330355) was initiated
at 11 sites in the US between May 2011 and October 2012.
Eligible subjects were aged B31 days, with a clinical
diagnosis of acute bacterial conjunctivitis in one or both
eyes, and a severity of grade C1 for both conjunctival
discharge and conjunctival hyperemia in the same eye
(each rated on a scale of 0 [absent/normal] to 3 [severe]).
Subjects with suspected fungal, protozoal, or viral etiology
in either eye, evidence of chemical or physical trauma to
either eye or ocular adnexa, and subjects with corneal
infiltrates or ulcer in either eye were excluded. Use of
systemic or topical non-prophylactic antimicrobial therapy
within 96 h of day 1 (baseline), or expected use of such
during the study period, was not allowed. Subjects who had
received topical antimicrobial therapy for routine prophy-
laxis (e.g. at the time of birth) could be enrolled 24 h or
more after the last application of antibiotic prophylaxis.
Systemic or topical antimicrobials were not allowed to be
used by the breastfeeding mother or wet nurse. Subjects
were also excluded if they required concomitant use of
ophthalmic (either eye) or systemic corticosteroids, sys-
temic non-steroidal anti-inflammatory drugs (NSAIDs),
systemic antihistamines, or ocular immunosuppressants.
The study was conducted in accordance with Good Clinical
Practice (as described in the International Conference on
Harmonisation guidelines), applicable local regulations,
and the ethical principles in the Declaration of Helsinki.
The protocol was approved by the Institutional Review
Boards associated with individual study sites, and written
informed consent was obtained by each subject’s parent or
legally authorized representative prior to study
participation.
Subjects who met the eligibility criteria had an initial
eye examination that included an assessment of ocular
signs, and had a conjunctival swab taken for culture from
the affected eye(s). Subjects were then randomly assigned
in a 1:1 ratio, according to a computer-generated ran-
domization list, to receive besifloxacin or gatifloxacin
instilled in the affected eye(s) three times daily for 7 days.
The randomization list was produced prior to study
enrollment by an unmasked statistician. The investigator,
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the subject’s parent/authorized representative, and all study
personnel involved in study conduct and monitoring were
masked to the study treatment identity. Masking was
accomplished by replacing the commercial labeling on
besifloxacin and gatifloxacin bottles with identical inves-
tigational labels and packaging them in identical kit boxes.
A designee at each study site was given responsibility for
dispensing/collecting study materials to subjects. The first
dose of study medication was instilled in the clinic fol-
lowing the initial eye examination and conjunctival culture.
Parents/guardians were instructed to continue administra-
tion of study treatment at approximately 6 h intervals. Both
remaining doses on day 1 were to be administered, even if
the resulting intervals were shorter than 6 h.
Following the day 1/start of treatment visit, subjects
returned to the clinic at visit 3 (day 4 ± 1) and visit 5 (day
8 or 9) for clinical assessment of ocular signs and culture of
the affected eye(s). Vital signs and body weight measure-
ments were taken, an ocular examination of both eyes was
performed, and ocular and non-ocular adverse events (AEs)
were recorded. Ocular examinations consisted of assess-
ment of light perception, eyelid edema, conjunctival
chemosis, the pupillary reflex, and the red reflex test, as
well as clinical examination of the eyelid (other than eyelid
edema), the conjunctiva (other than conjunctival discharge,
conjunctival hyperemia, and conjunctival chemosis), and
the cornea. All assessments were performed in both eyes,
with the exception of microbial cultures, which were taken
from baseline-affected eyes only. A physical examination
was also conducted at visit 5. In addition to the clinic visits,
parents/guardians were asked to complete a telephone
contact at visits 2 (day 2) and 4 (day 6 or 7) to confirm their
compliance with dosing and to solicit AEs.
At each visit, samples were obtained from the conjuncti-
val cul-de-sac of baseline-affected eye(s) using a sterile
swab, and the swabs were sent to Covance Central Labora-
tory Services, Inc. (Indianapolis, IN, USA) for quantitative
bacteriological analysis. Subjects were considered culture-
positive or culture-confirmed if the bacterial colony count for
a particular species (in colony forming units per mL; CFU/
mL) equaled or exceeded the threshold value for that species
on the Cagle list, as modified by Leibowitz [24, 25]. For
isolates that met/exceeded the bacterial threshold, minimum
inhibitory concentration (MIC) testing was performed for
besifloxacin and comparator antibacterial agents following
procedures recommended by the Clinical and Laboratory
Standards Institute [26].
2.2 Outcomes
Primary endpoints included clinical resolution (binary
outcome [yes/no], with clinical resolution defined as the
absence of both conjunctival discharge and conjunctival
hyperemia; severity grade = 0 at visit 5) and rates of
ocular and non-ocular treatment-emergent AEs (TEAEs).
Ocular discharge was rated on a scale of 0 (absent), 1
(mild), 2 (moderate), and 3 (severe), and conjunctival
hyperemia was rated on a scale of 0 (normal), 1 (mild), 2
(moderate), and 3 (severe). Secondary endpoints included
clinical resolution at visit 3 and bacterial eradication at
visits 3 and 5 in culture-positive eyes. Bacterial eradication
(binary outcome [yes/no]) was defined as the absence of all
ocular bacterial species that were present at or above
threshold at visit 1. Eradication of individual bacterial
species was another secondary endpoint.
All TEAEs (ocular and non-ocular) observed by the
investigator or reported by the subject’s parent/guardian
were recorded using the Medical Dictionary for Regulatory
Activities (version 15.1) body system and preferred terms,
and characterized as mild, moderate, or severe. The
investigator also evaluated the relationship of AEs to study
treatment. Secondary safety outcomes included the results
of ocular examinations, physical examination, and vital
signs. Ocular examinations included light perception
assessment (present or absent), eyelid edema and con-
junctival chemosis (each rated on a scale from 0 = none to
3 = severe), and pupillary reflex and red reflex test (rated
as normal or abnormal).
2.3 Statistical Analyses
With the exception of the endpoint of individual or species-
specific bacterial eradication, one eye per subject was
designated as the study eye for analysis of efficacy end-
points. In subjects with bilateral conjunctivitis, the study
eye was the eye with the highest combined sum of ratings
(i.e. severity) for ocular discharge and conjunctival
hyperemia at baseline. For cases in which baseline severity
ratings were equal for both eyes, the right eye was desig-
nated as the study eye. In the analyses by individual bac-
terial species, non-study eyes (i.e. fellow eyes) could
contribute data provided the severity of conjunctivitis in
that eye met the inclusion criteria and the bacterial species
that was at or above threshold in that eye at baseline was
different from the species cultured from the study eye.
The primary population for the efficacy analysis was the
intent-to-treat (ITT) population, which included all ran-
domized subjects. Additional analyses, including all analy-
ses on bacterial endpoints, were performed in the modi-
fied ITT (mITT) population, which was defined as sub-
jects in the ITT population with baseline bacterial culture
at or above threshold for any accepted ocular bacterial
species. The safety population included all subjects who
received at least one dose of study drug as part of the
protocol and who had at least one post-treatment safety
assessment.
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Efficacy findings for baseline-designated study eyes and
treated fellow eyes were summarized using descriptive
statistics, with missing data imputed using the last obser-
vation carried forward. Differences between treatments in
clinical resolution and bacterial eradication were evaluated
for baseline-designated study eyes only using the asymp-
totic Pearson Chi-square test. All analyses were performed
using Statistical Analysis Software version 9.1 (SAS
Institute, Inc., Cary, NC, USA). Safety results were
reported using descriptive statistics.
The study initially sought to enroll 200 subjects (100 per
treatment group) to obtain 100 culture-positive subjects,
but was terminated early due to a low enrollment rate
unrelated to safety or efficacy concerns.
3 Results
3.1 Subjects and Baseline Pathogens
A total of 33 subjects (besifloxacin, n = 16; gatifloxacin,
n = 17), all neonatal (\28 days), were enrolled at seven
clinical sites and comprised the ITT population. Of the 33
enrolled subjects, 32 (97%) completed the study; one
subject randomized to gatifloxacin withdrew consent and
discontinued. Twenty-two subjects (besifloxacin, n = 13;
gatifloxacin, n = 9) had culture-positive conjunctivitis in at
least one eye and were included in the mITT population.
Demographic characteristics of the ITT and mITT popu-
lations are provided in Table 1. There were no apparent
differences in demographic characteristics between treat-
ment groups. Overall, the mean (± standard deviation) age
of subjects was 15.5 days (6.0) and 15.7 days (5.3), and
57.6% and 54.5% of subjects in the ITT and mITT popu-
lations, respectively, were female.
Table 2 presents bacterial pathogens above threshold
isolated at baseline from all culture-positive eyes, along
with the MIC of besifloxacin and gatifloxacin for these
isolates. A total of 50 bacterial isolates meeting threshold
criteria for pathogenicity in bacterial conjunctivitis were
identified, and most were Gram-positive. The most com-
mon Gram-positive bacterial species cultured were
Streptococcus mitis, Staphylococcus epidermidis, and
Staphylococcus aureus, while the most common Gram-
negative bacterial species cultured was Moraxella catar-
rhalis. Overall, the MIC or range of MICs (in cases of
more than one isolate) for besifloxacin appeared lower to
those noted with gatifloxacin for Gram-positive organ-
isms; for Gram-negative organisms, besifloxacin MICs




Table 3 presents clinical resolution rates at visits 3 and 5.
In the ITT population, clinical resolution at visit 5 (day 8 or
9; primary efficacy endpoint) was observed in 75.0% of
study eyes treated with besifloxacin, compared with 70.6%
of study eyes treated with gatifloxacin (p = 0.78). In the
mITT population, clinical resolution at visit 5 was observed
in 84.6% of besifloxacin-treated study eyes compared with
77.8% of gatifloxacin-treated study eyes (p = 0.68). At
visit 3 (day 4 ± 1), clinical resolution rates were 18.8 vs.
29.4% (ITT population) and 7.7 vs. 33.3% (mITT popu-
lation) in besifloxacin- and gatifloxacin-treated eyes,
respectively (p C 0.13). In treated fellow eyes, patterns in
clinical resolution rates between treatment groups appeared
similar to those observed in study eyes at both visit 3 and
visit 5 (statistical analyses not performed).
3.2.2 Bacterial Eradication
Figure 1 presents bacterial eradication rates at visits 3 and
5 for culture-positive, baseline-designated study eyes
(mITT population). There was a significant difference
between treatments in favor of besifloxacin at visit 3 (84.6
vs. 44.4%; p = 0.0467) but not at visit 5 (92.3 vs. 88.9%:
p = 0.7839). Among treated fellow eyes, bacterial eradi-
cation at visit 3 was achieved in three of five eyes treated
with besifloxacin and two of three eyes treated with gati-
floxacin; at visit 5, bacterial eradication occurred in four of
five eyes treated with besifloxacin and all eyes (3/3) treated
with gatifloxacin.
Table 4 presents bacterial eradication data for indi-
vidual bacterial species at visits 3 and 5. As indicated
earlier, treated fellow eyes could contribute data if the
bacterial species isolated from that eye was different
from that cultured from the baseline-designated study
eye. At visit 3, 88.9% (16/18) of Gram-positive organ-
isms were eradicated in besifloxacin-treated eyes, com-
pared with 46.2% (6/16) in gatifloxacin-treated eyes. The
percentage of all culture-positive treated eyes showing
eradication of Gram-negative organisms by visit 3 was
100% (6/6) in the besifloxacin group and 75.0% (3/4) in
the gatifloxacin group. At visit 5, all species were
eradicated, with the only exceptions being Staphylo-
coccus epidermidis in a gatifloxacin-treated eye and
Staphylococcus hominis in a besifloxacin-treated eye.
However, the bacterial count for these isolates was
observed to be reduced to below threshold levels, with
no new species present in both cases.
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Table 1 Demographic characteristics
ITT population mITT population
Besifloxacin [n = 16] Gatifloxacin [n = 17] Besifloxacin [n = 13] Gatifloxacin [n = 9]
Age, days
Mean (SD) 15.8 (6.39) 15.2 (5.75) 15.9 (6.01) 15.4 (4.48)
Min, max 6, 26 5, 25 6, 25 11, 25
Gender
Male 4 (25.0) 10 (58.8) 3 (23.1) 7 (77.8)
Female 12 (75.0) 7 (41.2) 10 (76.9) 2 (22.2)
Race
Asian 1 (6.3) 1 (5.9) 1 (7.7) 1 (11.1)
Black/African American 0 1 (5.9) 0 1 (11.1)
White 12 (75.0) 12 (70.6) 10 (76.9) 6 (66.7)
Other 3 (18.8) 3 (17.6) 2 (15.4) 1 (11.1)
Data are expressed as n (%) unless otherwise specified
ITT intent-to-treat, mITT modified intent-to-treat, SD standard deviation, Min minimum, Max maximum
Table 2 Bacterial species




besifloxacin and gatifloxacin for
those isolates
Bacterial species No. of isolatesb Minimum inhibitory concentrations (lg/mL)
Besifloxacin Gatifloxacin
Gram-positive 38 0.015–8 0.06–64
CDC coryneform group G 1 0.03 0.06
Enterococcus faecalis 1 0.25 0.5
Lactococcus garvieae 1 0.5 0.5
Staphylococcus aureus 6 0.015–0.06 0.06–0.25
Staphylococcus epidermidis 9 0.03–8 0.06–64
Staphylococcus hominis 4 0.06 0.12–0.25
Staphylococcus warneri 1 0.12 0.25
Streptococcus mitis group 11 0.06–2 0.25–32
Streptococcus salivarius group 4 0.06–0.12 0.12–0.5
Gram-negative 12 0.03–4 0.03–1
Chryseobacterium indologenes 2 1 0.5
Chryseobacterium species 1 4 1
Elizabethkingia meningoseptica 1 1 0.25
Haemophilus influenzae 1 0.03 0.03
Leclercia adecarboxylata 1 0.06 0.03
Moraxella catarrhalis 4 0.06–0.12 0.03–0.06
Serratia marcescens 1 0.5 0.25
Wautersiella falsenii 1 0.5 0.5
CFU colony-forming units, CDC centers for disease control
a Threshold criteria were C1000 CFU/mL for the CDC coryneform group G; C100 CFU/mL for
Staphylococcus spp (except S. aureus); C10 CFU/mL for E. faecalis, L. garvieae, S. aureus, Streptococcus
spp, and M. catarrhalis; C1 CFU/mL for Gram-negative species (except M. catarrhalis)
b Number of times a specific bacterial species was isolated at or above threshold at baseline from study
eyes or treated fellow eyes
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3.3 Safety
Study eyes had a mean exposure of 6.94 (±0.25) and 6.65
(±1.46) days in the besifloxacin and gatifloxacin treatment
groups, respectively. The mean exposure for all treated eyes
(i.e. sum of study eye and treated fellow eye exposure) was
10.38 (±3.52) and 8.71 (±3.60) eye-days for the besifloxacin
and gatifloxacin treatment groups, respectively.
There were no serious AEs during the conduct of the
study. No TEAEs, either ocular or non-ocular, were
reported in either study or fellow eyes of subjects in the
besifloxacin treatment group. In the gatifloxacin treatment
group, a total of six AEs (five non-ocular, one ocular) were
reported. All AEs were mild or moderate in severity and
judged as ‘unrelated’ or ‘unlikely related’ to the study
drug. The one ocular AE consisted of mild bacterial con-
junctivitis in an initially untreated fellow eye, which
occurred after visit 1. The eye was treated with study
treatment (gatifloxacin) and then resolved. The five non-
ocular AEs occurring in four subjects included abdominal
pain, irritability, rhinorrhea, acne infantile, and dermatitis.
No AEs resulted in treatment discontinuation.
There were no meaningful findings noted for vital sign
measurements or results of ocular or physical examinations
performed during the study. In addition, there were no cases
of severe eyelid edema or severe chemosis at any visit, and all
cases of eyelid edema and chemosis resolved at visit 5.
Pupillary reflex, red reflex test, and light perception were
normal throughout the study. No major findings were iden-
tified on eyelid and conjunctival examinations in either
treatment group, and all corneal examinations were normal.
4 Discussion
In this report, we describe the results of a double-masked,
multicenter study comparing besifloxacin ophthalmic sus-
pension 0.6% with gatifloxacin ophthalmic solution 0.3%
Fig. 1 Bacterial eradication
rates at visits 3 and 5 (culture-
positive, baseline-designated
study eyes, modified intent-to-
treat population, last
observation carried forward).
p values from the Pearson Chi-
square test
Table 3 Clinical resolutiona at
visits 3 and 5 (LOCF)
Baseline-designated study eye [n/N (%)] Fellow treated eye [n/N (%)]
Besifloxacin Gatifloxacin p valueb Besifloxacin Gatifloxacin
Visit 3 (day 4 ± 1)
ITT population 3/16 (18.8) 5/17 (29.4) 0.48 1/8 (12.5) 2/5 (40.0)
mITT population 1/13 (7.7) 3/9 (33.3) 0.13 0/5 (0.0) 2/3 (66.7)
Visit 5c (day 8 or 9)
ITT population 12/16 (75.0) 12/17 (70.6) 0.78 5/8 (62.5) 2/5 (40.0)
mITT population 11/13 (84.6) 7/9 (77.8) 0.68 4/5 (80.0) 2/3 (66.7)
ITT intent-to-treat, mITT modified intent-to-treat, LOCF last observation carried forward
a Clinical resolution defined as the absence of both conjunctival discharge and conjunctival hyperemia
b Pearson Chi-square test; LOCF
c Primary outcome visit (study eye only)
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in 33 neonatal subjects with bacterial conjunctivitis. Other
than a study published in abstract form only [15], this is the
first published study evaluating the safety and efficacy of
two topical fluoroquinolones in neonatal patients with
bacterial conjunctivitis. Both besifloxacin and gatifloxacin
appeared to be well-tolerated in this group of neonates. No
TEAEs were reported in the besifloxacin group, and the six
AEs in the gatifloxacin group were not considered related
to treatment.
Both besifloxacin and gatifloxacin appeared effective for
clinical resolution in neonates with bacterial conjunctivitis.
The percentages of eyes showing clinical resolution were
not statistically different between the besifloxacin and
gatifloxacin groups at either visit 3 (day 4 ± 1) or visit 5
(day 8 or 9). However, the proportion of eyes showing
bacterial eradication was significantly higher in the besi-
floxacin group at visit 3, almost double that of the gati-
floxacin group. Besifloxacin has previously been shown to
have more rapid in vitro bactericidal activity compared
with gatifloxacin [27], possibly evidenced in the current
study by the higher rate of bacterial eradication at visit 3 in
the besifloxacin group. However, by visit 5 the two treat-
ment groups showed similarly high percentages of bacterial
eradication, likely due to the action of the antibacterial in
conjunction with the host immune response in this self-
limited condition. Bacterial eradication findings with
besifloxacin were consistent with rates observed at treat-
ment completion in several previous clinical studies
[28–30].
The range of MICs for cultured pathogens at baseline
differed somewhat between besifloxacin and gatifloxacin.
Besifloxacin MIC ranges appeared better (i.e. lower) than
gatifloxacin MIC ranges for Gram-positive pathogens,
while gatifloxacin MICs were similar or slightly better to
besifloxacin MICs for Gram-negative organisms. The
greatest differences in in vitro susceptibility between the
two antibacterials was noted among the Streptococcus mitis
group, for which besifloxacin MICs were 4- to 16-fold
lower than those for gatifloxacin. Yet, by visit 5, all S. mitis
organisms were found to have been eradicated in both
treatment groups, indicating that in vitro data may not
always predict in vivo efficacy when antibacterial drugs are
used topically in ocular infections. At visit 5, each treat-
ment group had one species-specific eye in which a bac-
terial species failed to be eradicated (S. epidermidis in a
gatifloxacin-treated eye and S. hominis in a besifloxacin-
treated eye); however, the bacterial count for these species
was reduced compared with visit 3.
Very little published data on the use of topical fluoro-
quinolones in neonates with bacterial conjunctivitis are
available. In a study published in abstract form only, 142
culture-positive patients\31 days of age received either
Table 4 Bacterial eradication
by species at visits 3 and 5,
mITT population (LOCF)
Bacterial species Species-specific study eye [n/N]
Besifloxacin Gatifloxacin
Visit 3 Visit 5 Visit 3 Visit 5
Gram-positive 16/18 17/18 6/13 12/13
CDC coryneform group G 1/1 1/1 – –
Enterococcus faecalis 1/1 1/1 – –
Lactococcus garvieae 1/1 1/1 – –
Staphylococcus aureus 3/3 3/3 1/2 2/2
Staphylococcus epidermidis 2/2 2/2 2/5 4/5
Staphylococcus hominis 1/2 1/2 0/1 1/1
Staphylococcus warneri – – 1/1 1/1
Streptococcus mitis group 5/6 6/6 2/3 3/3
Streptococcus salivarius group 2/2 2/2 0/1 1/1
Gram-negative 6/6 6/6 3/4 4/4
Chryseobacterium indologenes 1/1 1/1 – –
Chryseobacterium species 1/1 1/1 – –
Elizabethkingia meningoseptica – – 1/1 1/1
Haemophilus influenzae – – 1/1 1/1
Leclercia adecarboxylata 1/1 1/1 – –
Moraxella catarrhalis 2/2 2/2 1/1 1/1
Serratia marcescens – – 0/1 1/1
Wautersiella falsenii 1/1 1/1 – –
mITT modified intent-to-treat, LOCF last observation carried forward, CDC centers for disease control
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moxifloxacin or ciprofloxacin three times daily for 4 days;
at the test-of-cure visit (day 9), clinical cure was 80% for
both treatments, and microbiological eradication was 92%
versus 87% for moxifloxacin and ciprofloxacin, respec-
tively [15]. Both medications were well tolerated, with no
treatment-related serious AEs or treatment-related changes
in ocular and cardiovascular examination parameters. In an
analysis of safety data from five separate studies of moxi-
floxacin for the treatment of bacterial conjunctivitis, the
incidences of common AEs among subjects\28 days of
age (n = 100) were generally similar to or lower than the
incidences observed in other age groups, and there were no
serious AEs in newborns [11]. The findings from a study
comparing gatifloxacin (n = 84) and moxifloxacin
(n = 86) in neonates with conjunctivitis have been reported
on the ClinicalTrials.gov website [23]. Rates of non-serious
AEs (all ‘conjunctivitis’ or ‘conjunctivitis bacterial’) were
13.1% with gatifloxacin and 9.3% with moxifloxacin; one
serious AE (pyrexia) was reported in the moxifloxacin
group.
The major limitation of the current study was the small
sample size and resulting lack of statistical power, a con-
sequence of early study termination for low enrollment,
unrelated to safety concerns or efficacy findings. Despite
the smaller-than-planned population, the findings presented
are of interest simply because of the paucity of published
data on topical fluoroquinolone use in neonates. Further
studies of adequate sample size are required to confirm the
favorable efficacy and safety data observed in this study
and to add to the generalizability of the findings. No cases
of MRSA were identified in this small study. Antibiotic
efficacy against MRSA is increasingly being recognized as
a critical issue in the management of ocular bacterial
infections overall and among newborns [31, 32]. Notably,
in vitro susceptibility studies conducted over recent years
have demonstrated potent activity of besifloxacin against
ocular MRSA isolates compared with other antibiotics,
including other fluoroquinolones [19, 33]. If MRSA iso-
lates had been recovered in the current neonatal study,
potential differences between besifloxacin and gatifloxacin
may have been more apparent. Finally, the lack of a vehicle
control group did not allow for an efficacy comparison for
either fluoroquinolone versus no active treatment.
5 Conclusions
In this study of neonatal subjects with bacterial conjunc-
tivitis, the rates of clinical resolution and bacterial eradi-
cation were high and were similar in eyes treated with
besifloxacin compared with gatifloxacin after 7 days, while
bacterial eradiation appeared to be more rapid with besi-
floxacin use. While larger studies are warranted to confirm
these findings, both treatments were well-tolerated and no
safety concerns were noted in this small study.
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